Zacks Investment Research upgraded shares of Myovant Sciences Ltd (NASDAQ:MYOV) from a sell rating to a hold rating in a research note published on Friday.

According to Zacks, “Myovant Sciences Ltd. is a biopharmaceutical company. It focused on developing and commercializing therapies for women’s health diseases and other endocrine-related disorders, including advanced prostate cancer. The company’s product candidate consists of relugolix which are in clinical trial, an oral once-daily small molecule that acts as a gonadotropin-releasing hormone receptor antagonist. Myovant Sciences Ltd. is based in Hamilton, Bermuda. “

Separately, Evercore ISI initiated coverage on shares of Myovant Sciences in a report on Wednesday, August 16th. They set an outperform rating for the company. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. Myovant Sciences has a consensus rating of Buy and an average target price of $18.20.

Myovant Sciences (NASDAQ MYOV) traded down 3.12% during trading on Friday, reaching $13.95. 38,191 shares of the company were exchanged. The company’s market capitalization is $848.77 million. Myovant Sciences has a one year low of $9.92 and a one year high of $15.50. The firm’s 50-day moving average is $11.51 and its 200 day moving average is $11.91.

TRADEMARK VIOLATION NOTICE: This piece of content was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece of content on another site, it was stolen and republished in violation of U.S. and international copyright legislation. The legal version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/08/26/myovant-sciences-ltd-myov-upgraded-to-hold-at-zacks-investment-research.html.

A number of large investors have recently made changes to their positions in MYOV. Wells Fargo & Company MN raised its stake in shares of Myovant Sciences by 331.9% in the first quarter. Wells Fargo & Company MN now owns 16,527 shares of the company’s stock worth $194,000 after buying an additional 12,700 shares during the period. Bank of New York Mellon Corp raised its stake in shares of Myovant Sciences by 36.3% in the first quarter. Bank of New York Mellon Corp now owns 23,784 shares of the company’s stock worth $279,000 after buying an additional 6,330 shares during the period. Oxford Asset Management bought a new stake in shares of Myovant Sciences during the first quarter worth about $303,000. JPMorgan Chase & Co. raised its stake in shares of Myovant Sciences by 30.6% in the first quarter. JPMorgan Chase & Co. now owns 83,070 shares of the company’s stock worth $975,000 after buying an additional 19,474 shares during the period. Finally, BB Biotech AG raised its stake in shares of Myovant Sciences by 3.4% in the first quarter. BB Biotech AG now owns 3,302,835 shares of the company’s stock worth $38,775,000 after buying an additional 110,000 shares during the period.

About Myovant Sciences

Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for women’s health diseases and other endocrine-related disorders. Its main product candidate is Relugolix. Relugolix is an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and inhibits receptors in the anterior pituitary gland.

Analyst Recommendations for Myovant Sciences (NASDAQ:MYOV)

Receive News & Stock Ratings for Myovant Sciences Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myovant Sciences Ltd and related stocks with our FREE daily email newsletter.